Asahi Kasei Licenses Anti-glaucoma Drug to Altheos
Tokyo, Apr 9, 2010 (JCN) - Asahi Kasei Pharma has concluded a license agreement with US-based biopharmaceutical venture Altheos, Inc., granting Altheos exclusive rights to develop and sell Asahi Kasei Pharma's AK138-series compounds as novel anti-glaucoma therapy in all territories throughout the world outside Japan and Korea.
Research by Asahi Kasei Pharma has confirmed that the compounds of the AK138 series act as selective Rho-kinase inhibitors and show excellent potential to facilitate strong and lasting reduction of intraocular pressure.
Atheos will commence the development of a new anti-glaucoma drug referred to as ATS-907, with funding through venture capital investment.
Asahi Kasei Pharma is confident in the drug-development potential of Altheos, and will provide Altheos its thorough support in the development and sale of the new anti-glaucoma drug ATS-907, to contribute to the treatment of patients around the world.
Print
Alerts
